The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Zipradon     6-chloro-5-[2-[4-(7-thia-8...

Synonyms: Geodon, Zeldox, Ziprasidone, ziprasidona, ziprazidone, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Ziprasidone


Psychiatry related information on Ziprasidone


High impact information on Ziprasidone


Chemical compound and disease context of Ziprasidone


Biological context of Ziprasidone


Anatomical context of Ziprasidone


Associations of Ziprasidone with other chemical compounds


Gene context of Ziprasidone


Analytical, diagnostic and therapeutic context of Ziprasidone


  1. Six-month, blinded, multicenter continuation study of ziprasidone versus olanzapine in schizophrenia. Simpson, G.M., Weiden, P., Pigott, T., Murray, S., Siu, C.O., Romano, S.J. The American journal of psychiatry. (2005) [Pubmed]
  2. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Glassman, A.H., Bigger, J.T. The American journal of psychiatry. (2001) [Pubmed]
  3. Ziprasidone-related tardive dyskinesia. Keck, M.E., Müller, M.B., Binder, E.B., Sonntag, A., Holsboer, F. The American journal of psychiatry. (2004) [Pubmed]
  4. Ziprasidone alternative for olanzapine-induced hyperglycemia. Spivak, B., Alamy, S.S., Jarskog, L.F., Sheitman, B.B., Lieberman, J.A. The American journal of psychiatry. (2002) [Pubmed]
  5. Parkinsonism with intramuscular ziprasidone. Bilal, L., Tsai, C., Gasper, J.J., Ndlela, J.C. The American journal of psychiatry. (2005) [Pubmed]
  6. Sudden akathisia after a ziprasidone dose reduction. Oral, E.T., Altinbas, K., Demirkiran, S. The American journal of psychiatry. (2006) [Pubmed]
  7. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Breier, A., Berg, P.H., Thakore, J.H., Naber, D., Gattaz, W.F., Cavazzoni, P., Walker, D.J., Roychowdhury, S.M., Kane, J.M. The American journal of psychiatry. (2005) [Pubmed]
  8. Ziprasidone-induced acute dystonic reactions in patients with bipolar disorder. Weinstein, S.K., Adler, C.M., Strakowski, S.M. The Journal of clinical psychiatry. (2006) [Pubmed]
  9. Efficacy of ziprasidone against hostility in schizophrenia: Post hoc analysis of randomized, open-label study data. Citrome, L., Volavka, J., Czobor, P., Brook, S., Loebel, A., Mandel, F.S. J. Clin. Psychiatry (2006) [Pubmed]
  10. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Stroup, T.S., Lieberman, J.A., McEvoy, J.P., Swartz, M.S., Davis, S.M., Rosenheck, R.A., Perkins, D.O., Keefe, R.S., Davis, C.E., Severe, J., Hsiao, J.K. The American journal of psychiatry. (2006) [Pubmed]
  11. Ziprasidone-induced acute dystonia. Mason, M.N., Johnson, C.E., Piasecki, M. The American journal of psychiatry. (2005) [Pubmed]
  12. Prolactin elevation with ziprasidone. Lusskin, S.I., Cancro, R., Chuang, L., Jacobson, J. The American journal of psychiatry. (2004) [Pubmed]
  13. Physical health monitoring of patients with schizophrenia. Marder, S.R., Essock, S.M., Miller, A.L., Buchanan, R.W., Casey, D.E., Davis, J.M., Kane, J.M., Lieberman, J.A., Schooler, N.R., Covell, N., Stroup, S., Weissman, E.M., Wirshing, D.A., Hall, C.S., Pogach, L., Pi-Sunyer, X., Bigger, J.T., Friedman, A., Kleinberg, D., Yevich, S.J., Davis, B., Shon, S. The American journal of psychiatry. (2004) [Pubmed]
  14. Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone. Yang, S.H., McNeely, M.J. The American journal of psychiatry. (2002) [Pubmed]
  15. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Melkersson, K., Dahl, M.L. Drugs (2004) [Pubmed]
  16. Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. Anghelescu, I., Wolf, J. The Journal of clinical psychiatry. (2004) [Pubmed]
  17. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group. Brook, S., Lucey, J.V., Gunn, K.P. The Journal of clinical psychiatry. (2000) [Pubmed]
  18. Tolerability of ziprasidone: an expanding perspective. Daniel, D.G. The Journal of clinical psychiatry. (2003) [Pubmed]
  19. Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Cohen, S., Fitzgerald, B., Okos, A., Khan, S., Khan, A. The Journal of clinical psychiatry. (2003) [Pubmed]
  20. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Preskorn, S.H. Clinical pharmacokinetics. (2005) [Pubmed]
  21. The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice. Stahl, S.M., Shayegan, D.K. The Journal of clinical psychiatry. (2003) [Pubmed]
  22. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. Beedham, C., Miceli, J.J., Obach, R.S. Journal of clinical psychopharmacology. (2003) [Pubmed]
  23. A model for antipsychotic-induced obesity in the male rat. Minet-Ringuet, J., Even, P.C., Lacroix, M., Tomé, D., de Beaurepaire, R. Psychopharmacology (Berl.) (2006) [Pubmed]
  24. An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. Wu, L., Shryock, J.C., Song, Y., Belardinelli, L. J. Pharmacol. Exp. Ther. (2006) [Pubmed]
  25. 5-HT(1A) receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Rollema, H., Lu, Y., Schmidt, A.W., Sprouse, J.S., Zorn, S.H. Biol. Psychiatry (2000) [Pubmed]
  26. A comparison of the effects of loxapine with ziprasidone and thioridazine on the release of dopamine and acetylcholine in the prefrontal cortex and nucleus accumbens. Li, Z., Ichikawa, J., Meltzer, H.Y. Psychopharmacology (Berl.) (2003) [Pubmed]
  27. Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Su, Z., Chen, J., Martin, R.L., McDermott, J.S., Cox, B.F., Gopalakrishnan, M., Gintant, G.A. Biochem. Pharmacol. (2006) [Pubmed]
  28. The effects of ziprasidone on regional c-Fos expression in the rat forebrain. Jennings, C.A., Cluderay, J.E., Gartlon, J., Cilia, J., Lloyd, A., Jones, D.N., Southam, E. Psychopharmacology (Berl.) (2006) [Pubmed]
  29. Schizophrenia: genesis, receptorology and current therapeutics. Capuano, B., Crosby, I.T., Lloyd, E.J. Current medicinal chemistry. (2002) [Pubmed]
  30. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. Goff, D.C., Posever, T., Herz, L., Simmons, J., Kletti, N., Lapierre, K., Wilner, K.D., Law, C.G., Ko, G.N. Journal of clinical psychopharmacology. (1998) [Pubmed]
  31. The anxiolytic effect of the novel antipsychotic ziprasidone compared with diazepam in subjects anxious before dental surgery. Wilner, K.D., Anziano, R.J., Johnson, A.C., Miceli, J.J., Fricke, J.R., Titus, C.K. Journal of clinical psychopharmacology. (2002) [Pubmed]
  32. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Stroup, T.S., McEvoy, J.P., Swartz, M.S., Byerly, M.J., Glick, I.D., Canive, J.M., McGee, M.F., Simpson, G.M., Stevens, M.C., Lieberman, J.A. Schizophrenia bulletin. (2003) [Pubmed]
  33. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Weiden, P.J., Newcomer, J.W., Loebel, A.D., Yang, R., Lebovitz, H.E. Neuropsychopharmacology (2008) [Pubmed]
  34. Interactions between the cytochrome P450 system and the second-generation antipsychotics. Prior, T.I., Baker, G.B. Journal of psychiatry & neuroscience : JPN. (2003) [Pubmed]
  35. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Prakash, C., Kamel, A., Cui, D., Whalen, R.D., Miceli, J.J., Tweedie, D. British journal of clinical pharmacology. (2000) [Pubmed]
  36. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. Seeger, T.F., Seymour, P.A., Schmidt, A.W., Zorn, S.H., Schulz, D.W., Lebel, L.A., McLean, S., Guanowsky, V., Howard, H.R., Lowe, J.A. J. Pharmacol. Exp. Ther. (1995) [Pubmed]
  37. Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. Díaz-Mataix, L., Scorza, M.C., Bortolozzi, A., Toth, M., Celada, P., Artigas, F. J. Neurosci. (2005) [Pubmed]
  38. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Mamo, D., Kapur, S., Shammi, C.M., Papatheodorou, G., Mann, S., Therrien, F., Remington, G. The American journal of psychiatry. (2004) [Pubmed]
  39. A retrospective study of the safety of intramuscular ziprasidone in agitated elderly patients. Greco, K.E., Tune, L.E., Brown, F.W., Van Horn, W.A. The Journal of clinical psychiatry. (2005) [Pubmed]
WikiGenes - Universities